COMBINATION OF A MEK INHIBITOR AND A B-RAF INHIBITOR

Abstract

A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)6S-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-al]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2 / 6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the same and methods of using such combinations and compositions in the treatment of conditions in which inhibition of MEK and / or B-Raf is beneficial, e.g. cancer